Gyre Therapeutics (GYRE) Change in Cash (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Change in Cash data on file, last reported at $431000.0 in Q1 2026.

• Change in Cash for Q1 2026 came in at $431000.0, down 86.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.5 million (up 252.35% YoY), and the FY2025 annual result was $25.3 million, up 216.41% from the prior year.
• Change in Cash grew to $431000.0 in Q1 2026 per GYRE's latest filing, from -$3.3 million in the prior quarter.
• Over five years, Change in Cash peaked at $40.6 million in Q2 2022 and troughed at -$52.3 million in Q3 2022.
• A 5-year average of $429294.1 and a median of $431000.0 in 2026 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash slumped 261.62% in 2022, then jumped 1793.07% in 2025.
• A 5-year view of Change in Cash shows it stood at $16.2 million in 2022, then slumped by 54.22% to $7.4 million in 2023, then sank by 154.55% to -$4.1 million in 2024, then increased by 17.79% to -$3.3 million in 2025, then surged by 112.94% to $431000.0 in 2026.
• Business Quant data shows GYRE's Change in Cash at $431000.0 in Q1 2026, -$3.3 million in Q4 2025, and $3.9 million in Q3 2025.